Albany, NY -- (SBWIRE) -- 12/12/2019 -- Adrenoleukodystrophy Market Insights, Epidemiology and Market Forecast-2028

(Albany, US) DelveInsight launched a new report on Adrenoleukodystrophy Market Insights, Epidemiology and Market Forecast-2028

Some of the key facts of the report

1. Adrenoleukodystrophy is a deadly genetic disease that affects 1 in 18,000 people.
2. The United States has the highest Adrenoleukodystrophy prevalent population than EU5 and Japan. In 2017, the male prevalent population of Adrenoleukodystrophy in the United States was 7777.
3. In Germany, the prevalence trend of the types of Adrenoleukodystrophy follows the US trend of prevalence.

Key benefits of the report

1. Adrenoleukodystrophy Market report covers a descriptive overview and comprehensive insight of the Adrenoleukodystrophy epidemiology and Adrenoleukodystrophy market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Adrenoleukodystrophy market report provides insights on the current and emerging therapies.
3. Adrenoleukodystrophy Market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Adrenoleukodystrophy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Adrenoleukodystrophy market.

Request for sample pages

"Total Adrenoleukodystrophy Prevalent cases in seven major markets was 27,011 in 2017. The United States has the maximum prevalent cases, whereas, in Europe, Germany has the maximum cases followed by the UK and France."

Adrenoleukodystrophy market is segmented into Addison's Disease/Adrenal Insufficiency, Adrenomyeloneuropathy and cerebral Adrenoleukodystrophy. Majority of the market is dominated by cerebral Adrenoleukodystrophy, followed by Adrenomyeloneuropathy. Cerebral Adrenoleukodystrophy market is further sub-categorized by childhood cerebral Adrenoleukodystrophy [cCALD], adolescent cerebral Adrenoleukodystrophy [adCALD], and adult cerebral Adrenoleukodystrophy [aCALD]. The therapeutic Adrenoleukodystrophy market in 7MM was USD 137.21 million in 2017, during the study period 2017-2028. The therapeutic Cerebral Adrenoleukodystrophy market represents around 90% of the total Adrenoleukodystrophy market was USD 135.69 million in 2017. The United States reports the largest market size of Adrenoleukodystrophy, as well as, Cerebral Adrenoleukodystrophy, in comparison to EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

With no approved therapy in the market, Adrenoleukodystrophy market share of the United States was estimated to be very low. However, with the approval of the upcoming therapies during the forecast period [2019-2028], it is expected that the United States shall account for the highest market size of Adrenoleukodystrophy as compared to the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan, owing to the highest number of prevalent population along with highest annual cost of therapy expected for the forthcoming products.
The current therapeutic market is being ruled solely by transplantation [for severe cases of cerebral Adrenoleukodystrophy] and steroids [in case of Adrenal insufficiency] in the absence of any approved pharmacological therapy for Adrenoleukodystrophy treatment in the United States. Stem cell transplant can be an option to slow or halt the progression of Adrenoleukodystrophy in children if the treatment is done early.

The launch of the emerging therapies is expected to significantly impact Adrenoleukodystrophy treatment scenario in the upcoming years:-
Drugs covered
1. Lenti D
2. MIN-102
3. MD1003

And many others

The key players in Adrenoleukodystrophy market are:
1. Minoryx Therapeutics
2. Bluebird Bio
3. MedDay Pharmaceuticals
And many others

Table of contents

1. Report Introduction
2. Key Insights
3. Adrenoleukodystrophy Market Overview at a Glance
4. Adrenoleukodystrophy Disease Background and Overview
5. Adrenoleukodystrophy Epidemiology and Patient Population
5.1. Key Findings
5.2. Disease Definition
5.3. Population and Forecast Parameters
5.4. 7MM Prevalent Population of Adrenoleukodystrophy
5.5. Country Wise-Epidemiology of Adrenoleukodystrophy
5.5.1.United States
5.5.2.Germany
5.5.3.France
5.5.4.Italy
5.5.5.Spain
5.5.6.United Kingdom
5.5.7.Japan
6. Adrenoleukodystrophy Current Treatment and Medical Practices
7. Unmet Needs
8. Adrenoleukodystrophy Emerging Therapies
8.1. Key Cross Competition
8.1.1.Lenti D: Bluebird Bio
8.1.2.MIN-102: Minoryx Therapeutics
8.1.3.MD1003: MedDay Pharmaceuticals
9. Therapeutic Assessment
10. Adrenoleukodystrophy Market Analysis
11. Total Adrenoleukodystrophy Market Size in 7MM
12. The market size of Cerebral Adrenoleukodystrophy in 7MM
13. Adrenoleukodystrophy Market Size by Country
13.1. United States Market Analysis
13.2. EU-5: Market Analysis
13.2.1. Germany
13.2.2. France
13.2.3. Italy
13.2.4. Spain
13.3. Japan: Market Analysis
14. Market Drivers
15. Market Barriers
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight